MEGIN Installs the First MEG Maps™ Enabled TRIUX™ neo at the National Institute for Minamata Disease

HELSINKI, FINLAND. April 30, 2026 – MEGIN, the global leader in magnetoencephalography (MEG) solutions, has installed a MEG Maps™ enabled TRIUX™ neo, which supports MEGreview™ at the National Institute for Minamata Disease (NIMD) in Minamata, Japan.

This marks the first installation of the MEG Maps™ Platform in Japan. The system further expands MEGIN’s presence in the region as part of broader expansion across Asia-Pacific, as institutions advance capabilities in epilepsy presurgical evaluation, functional brain mapping, and neuroscience research. NIMD has been a long-standing user of MEG technology, establishing its program in 2009 to support the evaluation of methylmercury-related neurological conditions and ongoing research into Minamata disease. The installation represents an upgrade of its existing MEGIN system, supporting the next phase of its clinical and research activities.

The TRIUX™ neo system provides non-invasive measurement of brain activity with millisecond temporal resolution and high spatial accuracy, supporting applications including presurgical evaluation, functional brain mapping, and the study of neurological disorders. The MEG Maps™ Platform extends these capabilities through advanced data analysis and visualization tools designed to support both clinical interpretation and research workflows.

“Japan has played a significant role in the clinical and research use of MEG, and this installation at NIMD reflects the continued development of MEG programs within leading institutions,” said Gordon Baltzer, President of MEGIN. “The introduction of the MEG Maps™ enabled TRIUX™ neo, supports the next phase of this development, as institutions expand both clinical and research applications.”

“We are seeing continued investment in MEG from both new and existing institutions, with organizations continuing to expand their capabilities over time,” said Jim Petite, Head of Sales, North America at MEGIN. “Installations such as NIMD reflect how MEG programs develop, with customers building on established systems to support a broader range of clinical and research applications.”

The installation at NIMD forms part of MEGIN’s broader global activity, including both new system installations and upgrades across its installed base. This development reflects continued expansion of MEG across Asia-Pacific, alongside sustained adoption in other key markets, as institutions invest in these capabilities in response to increasing demand for non-invasive neurological evaluation and functional brain mapping.

About MEGIN

MEGIN is a global neuroscience technology company focused on developing innovative solutions for functional brain mapping for presurgical evaluation. For over 30 years, MEGIN has remained the global leader in MEG technology. Headquartered in Helsinki, Finland, MEGIN operates across Europe, North America, and Asia-Pacific. The TRIUX™ neo provides a non-invasive, real-time view of patient-specific neural activity with millimeter accuracy and millisecond resolution, providing the most precise information currently available on the market, installed in leading hospitals and research institutions worldwide.

Copyright 2026 © MEGIN – TRIUX™ neo is available for sale in the European Union, UK, Japan, Canada, the United States, as well as certain other countries. In other geographical areas, contact your local MEGIN representative. TRIUX™ neo is intended for use as a magnetoencephalographic (MEG) device that non-invasively detects and displays biomagnetic signals produced by electrically active nerve tissue in the brain. When interpreted by a trained clinician, the data enhances the diagnostic capability by providing useful information about the location relative to the brain anatomy of active nerve tissue responsible for critical brain functions. Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.

Website
www.megin.com

Sales & Media Contact
info@megin.com